Hot Low Price Stocks To Invest In 2019

A few days ago, an article about Nike (NYSE:NKE) argued that “Nike’s shares aren’t priced to buy.” The reasoning was that “Nike is, at best, fairly valued. And it certainly isn’t trading hands at fire-sale prices.” The question is: should you expect (and wait for) fire-sales prices? Most value investors know the maxim that it is better to buy a great business at a fair price than to buy a mediocre business at low price. We think that Nike is a great business at a fair price. We have been waiting for Nike’s price to come down for a long time and meanwhile, we have sold PUT options, though unfortunately these options have never been exercised (but we cashed-in premiums). Today, we bought the stock.

Reasons to avoid the stock

We invest with a long-term view and therefore we ask long-term questions:

Has the management of Nike changed its strategy? Is Nike’s long-term strategy ultimately going to fail? Is there anything that can or has damaged the Nike brand?

Of course, competition is there, but is there any industry where there is no long-term competition? Under Armour (NYSE:UAA), Adidas (OTCQX:ADDDF), Lululemon (NASDAQ:LULU) are all good companies, but they have always been there. Under Armour and Lululemon are perceived as new entrants, but they were actually founded 20 years ago (in 1996 and 1998), Adidas is almost a century old, while Nike is “only” 52-years old. So, what has changed? These industries move in waves, but the quality of the Nike brand, its management, and innovation have been a constant. In sum, if your answer to any of the previous questions is YES, then you should reconsider our investment thesis. If it is NO, then we can move on to the next paragraph.

Hot Low Price Stocks To Invest In 2019: Agenus Inc.(AGEN)

Advisors’ Opinion:

  • [By Max Byerly]

    Agenus (NASDAQ:AGEN) shares traded up 5.6% during mid-day trading on Thursday . The stock traded as high as $3.44 and last traded at $3.60. 39,070 shares were traded during mid-day trading, a decline of 97% from the average session volume of 1,431,827 shares. The stock had previously closed at $3.41.

  • [By Shane Hupp]

    Shares of Agenus (NASDAQ:AGEN) dropped 9.8% during trading on Monday following a dissappointing earnings announcement. The stock traded as low as $3.30 and last traded at $3.32. Approximately 2,421,286 shares changed hands during mid-day trading, an increase of 53% from the average daily volume of 1,586,724 shares. The stock had previously closed at $3.68.

  • [By Cory Renauer]

    Attention bargain shoppers: There could be some deals in aisle biotech.Agenus Inc.(NASDAQ:AGEN)andRegeneron Pharmaceuticals (NASDAQ:REGN) dished out some disappointing losses in recent months, but the market’s reaction to recent events seems a bit overdone.

  • [By Cory Renauer]

    Harnessing the power of the immune system to fight cancer is a big deal and Agenus Inc. (NASDAQ:AGEN) looks like a great way to follow the trend. This stock trades like a small-cap biotech, but a couple of candidates coming through its pipeline could help push annual revenue past the $1 billion mark. Plus, by this time next year, the company could have half a dozen or so new candidates in clinical trials.

Hot Low Price Stocks To Invest In 2019: Gilead Sciences, Inc.(GILD)

Advisors’ Opinion:

  • [By George Budwell]

    Bellicum is attempting to bring a safer and more potent form of adoptive cell therapy to market for a variety of cancers and orphan inherited blood disorders. By doing so, the company hopes to overcome the extensive leads currently held by the FDA-approved therapies ofGilead Sciences (NASDAQ:GILD) — via its acquisition of Kite Pharma, and Novartis (NYSE:NVS).

  • [By ]

    What should investors do with shares of Celgene (CELG) , Biogen Idec (BIIB) , Gilead Science (GILD) and Regeneron (REGN) ? Cramer once proclaimed these high-fliers his “four horsemen of biotech,” but lately they’ve lost all of their traction, with Celgene down 21%, Biogen off 14%, Gilead down 9% and Regeneron off 23% so far this year.

  • [By Todd Campbell, Sean Williams, and Brian Feroldi]

    There’s no telling if the data will be good, but if it is, Galapagos could benefit significantly from milestone payments and royalties. For instance, its lead product, filgotinib, is licensed to biotech Goliath Gilead Sciences(NASDAQ:GILD) and is being evaluated in a variety of blockbuster autoimmune indications. Results from a phase 3 rheumatoid arthritis study should be available in the second half of 2018; since that market is worth more than $16 billion per year, the payoff for investors could be big. Galapagos will share in EU profits on filgotinib, plus it can collect 20% to 30% royalties on U.S. sales if filgotinibeventually wins an OK.

  • [By Cory Renauer]

    Biotech traders get heaps of attention, but buying promising young drugmakers and holding them for the long term is a far easier way to get rich. Case in point: Spreading $10,000 evenly among shares of Biogen Inc. (NASDAQ:BIIB),Celgene Corporation (NASDAQ:CELG), andGilead Sciences Inc.(NASDAQ:GILD) around this time in 1998 would have made you a millionaire already.

Hot Low Price Stocks To Invest In 2019: Farmer Brothers Company(FARM)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Farmer Brothers (FARM)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Low Price Stocks To Invest In 2019: Enerplus Corporation(ERF)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Enerplus (NYSE:ERF) (TSE:ERF) – Stock analysts at National Bank Financial reduced their FY2018 earnings estimates for Enerplus in a research note issued on Thursday, May 3rd. National Bank Financial analyst T. Wood now forecasts that the oil and natural gas company will earn $1.13 per share for the year, down from their previous estimate of $1.27. National Bank Financial also issued estimates for Enerplus’ FY2019 earnings at $1.96 EPS.

Hot Low Price Stocks To Invest In 2019: KBR, Inc.(KBR)

Advisors’ Opinion:

  • [By ]

    KBR (NYSE: KBR)
    Though an under-the-radar name, KBR was the construction arm of oilfield services giant Halliburton (NYSE: HAL) before being spun off. With a consolidated market cap of $2.6 billion, KBR describes itself, per its website, as a “global provider of differentiated professional services and technologies within the Government Services and Hydrocarbon sectors.”

Leave a Reply

Your email address will not be published. Required fields are marked *